Ex vivo air-liquid interface respiratory mucosa platform to study type 2-driven Asthma. Intili G, Fucarino A, Burgio S, Amico MD, et al. J Asthma 2025 Dec 26:1-15. doi: 10.1080/02770903.2025.2608988.

Read + Share

Amedeo Smart

Independent Medical Education

Intili G, Fucarino A, Burgio S, Amico MD, et al. Ex vivo air-liquid interface respiratory mucosa platform to study type 2-driven Asthma. J Asthma 2025 Dec 26:1-15. doi: 10.1080/02770903.2025.2608988.
PMID: 41452274